ORIC Pharmaceuticals, Inc. ORIC announced that it has collaborated with pharma giants Bayer BAYRY and Janssen Research & Development, LLC, a Johnson & Johnson JNJ company, to support its ongoing study ...
Financial Position: ORIC ended 2023 with $235.0 million in cash, cash equivalents, and investments, bolstered by $210 million from private placements. R&D Investments: R&D expenses increased to $85.2 ...
Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20% ...
ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially “best-in-class” treatments. The company’s shares have not had a great year, returning ...
Hosted on MSN
Ladenburg Thalmann Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy Recommendation
Fintel reports that on July 8, 2025, Ladenburg Thalmann initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Buy recommendation. Analyst Price Forecast Suggests 80.92% Upside As of June ...
ORIC Pharmaceuticals, Inc. ORIC reported a loss for the fourth quarter on Monday. ORIC Pharmaceuticals posted a quarterly loss of 49 cents per share, in-line with market estimates, according to data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback